Screening of Anticancer Potential of Celecoxib and its Derivatives |
Park, Jeong-Ran
(Catholic Res Inst of Med Sci)
Kang, Jin-Hyoung (Catholic Cancer Center, The Catholic Univ of Korea) Kuh, Hyo-Jeong (Catholic Res Inst of Med Sci) Noh, Ji-Young (Inst of Sci & Tech, CJ Corp.) Ryu, Hyung-Chul (Inst of Sci & Tech, CJ Corp.) Park, Sang-Wook (Inst of Sci & Tech, CJ Corp.) Ko, Dong-Hyun (Inst of Sci & Tech, CJ Corp.) Cho, Il-Hwan (Inst of Sci & Tech, CJ Corp.) Lee, Joo-Y. (Dept of Nutrition, Univ of California, Davis, and Western Human Nutrition Res Ctr, ARS-USDA) Hwang, Daniel-H. (Dept of Nutrition, Univ of California, Davis, and Western Human Nutrition Res Ctr, ARS-USDA) Kim, In-Kyung (Catholic Res Inst of Med Sci) |
1 | S.J. Baek, L.C. Wilson, C.H. Lee and T.E. Eling, Dual function of nonsteroidal anti-inflammatory drugs (NSAlDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacal. Exp. Ther., 301, 1126-1131 (2002) DOI ScienceOn |
2 | AL. Hsu, T.T. Ching, D.S. Wang, X. Song, Y.M. Rangnekar and C.S. Chen, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem.,275, 11397-11403 (2000) DOI ScienceOn |
3 | S. Arico, S. Pattingre, C. Bauvy, P. Gane, A. Barbat, P. Codogno and E. Ogier-Denis, Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Bioi.Chern., 277, 27613-27621 (2002) DOI |
4 | L.C. Hsi, S.l Baek and T.E. Eling, Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp. Cell Res., 256, 563-570 (2000) DOI ScienceOn |
5 | L. Milas, K. Kishi, N.Hunter, K. Mason, J.L. Masferrer and P.J. Tofilon, Enhancement of tumor response to gammaradiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst., 91, 1501-1504 (1999) DOI |
6 | T.Hida, K. Kozaki, H. Ito, O. Miyaishi, Y. Tatematsu, T. Suzuki, K. Matsuo, T. Sugiura, M. Ogawa, T. Takahashi and T. Takahashi, Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res., 8, 2443-2447 (2002) |
7 | K. Wakitani, T Nanayama, M. Masaki and M. Matsushita, Profile of ITE-522 as a human cyclooxygenase-2 inhibitor. Jpn. J. Pharmacol., 78, 365-371 (1998) |
8 | Y. Mizutani, K. Kamoi, O. Ukimura, A. Kawauchi and T. Miki, Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J. Ural., 168, 2650-2654 (2002) DOI ScienceOn |
9 | X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp and C.S. Chen, Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst., 94, 585-591 (2002) DOI |
10 | T. Hida, K. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa and T. Takahashi, Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res., 6, 2006-2011 (2000) |
11 | A.F. Soriano, B. Helfrich, D.C. Chan, L.E. Heasley, PA. Jr. Bunn and T.C. Chou, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res., 59, 61786184 (1999) |
12 | R.E. Harris, Cycloxygenase-2, prostaglandins, and colorectal carcinogenesis. In COX-2 Blockade In Cancer Prevention and Therapy, Humana Press., pp. 160-164 (2003). |
13 | A.T. Koki and J.L. Masferrer, Celecoxib, a specific COX-2 inhibitor with anticancer properties, Cancer Control., 9, 28-35 (2002). DOI |
14 | S. I. Tegeder, E. Niederberger, L. Brautigam and G. Geisslinger, COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J., 15, 2742-2744(2001). DOI |
15 | M.M. Goldenberg, Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther., 21, 1497-1513; discussion 1427-1428 (1999) DOI ScienceOn |
16 | N.H. Holford and L.B. Sheiner, Kinetics of pharmacologic response. Pharmacal. Ther., 16, 143-166 (1982) DOI ScienceOn |
17 | J. Cheng, H. Imanishi, Y. Amuro and T. Hada, NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer., 99, 755-761 (2002) DOI ScienceOn |
18 | W.C. Hung, H.C. Chang, M.R. Pan, T.H. Lee and L.Y. Chuang, Induction of p27(KIPI) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol., 58, 1398-1403 (2000) DOI |
19 | Y. Araki, S. Okamura, S.P. Hussain, M. Nagashima, P. He, M. Shiseki, K. Miura and C.C. Harris, Regulation of cyclooxygenase-2 expression by the wnt and ras pathways. Cancer Res., 63, 728-734 (2003) |
20 | J.A. Han, J.I. Kim, P.P. Ongusaha, D.H Hwang, L.R. Ballou, A Mahale, S.A Aaronson and S.W Lee, p53mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. EMBO J., 21, 5635-5644 (2002) DOI ScienceOn |
21 | D.H. Hwang, V. Fung and A.J. Dannenberg, National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of Cox-dependent and independent mechanisms. Neoplasia., 4, 91-97 (2002) DOI ScienceOn |
22 | S.J. Baek, K.S. Kim, J.B. Nixon, L.C. Wilson and T.E. Eling, Cyclooxygenase inhibitors regulate the expression of a TGFbeta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol., 59, 901-908 (2001) DOI |